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INTRODUCTION
Since 2007, the Journal of Gynecologic Oncology has pub-
lished the annual review, “Major Clinical Research Advances in 
Gynecologic Cancer” in every December issue. Starting with 
the present review of 2011, the annual review will be included 
in the January issue of the next year, in this case, 2012. 
Several outstanding research studies were found in our 
search of major journals and presented abstracts in the same 
manner as previously described [1], which were then catego-
rized into 11 themes: five are on ovarian cancer, three are on 
cervical cancer, one is on endometrial and two are on breast 
cancer. Notably, we included research advances in breast 
cancer in the review for the first time. Because breast cancer is 
associated with gynecologic cancers, particularly endometrial 
cancer, and thus, because gynecologic oncologists often man-
age patients with a history of breast cancer, updates of the 
current trends in breast cancer management are important. In 
this review, we summarized the valuable data of noteworthy 
clinical trials and translational researches that are potentially 
practice changing in the field of gynecologic oncology.
PARADIGM SHIFT IN MANAGEMENT OF OVARIAN CANCER
Two large studies were published in 2011, both of which 
were heralded by many researchers as laying the foundation 
for a paradigm shift in the management of ovarian cancer. 
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The annual review of 2011 comprised 11 themes of major research achievements in gynecologic oncology including breast 
cancer. A potential paradigm shift in the management of ovarian cancer was reviewed through comprehensive genomic 
analyses and a tumor-specific new intraoperative fluorescence imaging technique using folate receptor-α targeted agent, 
which is expected to improve intraoperative staging and more radical cytoreduction. In addition, updates of bevacizumab 
and poly (ADP-ribose) polymerase inhibitors, risk-reducing salpingo-oophorectomy, and risk evaluation of pelvic mass were 
discussed. Regarding cervical cancer, this review covered new findings on human papillomavirus vaccines and human 
papillomavirus tests as well as the current status of clinical trials on locally advanced cervical cancer. The promising role of 
sentinel lymph node biopsy in the management of early stage endometrial cancer was followed by two notable clinical 
researches on: exemestane, an aromatase inhibitor, for the prevention of breast cancer and eribulin, a non-taxane microtubule 
dynamics inhibitor for the treatment of metastatic breast cancer. Lastly, in premenopausal women with breast cancer, the effect 
of gonadotropin-releasing hormone analogue on the occurrence of chemotherapy-induced early menopause was discussed.
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The first study was conducted by The Cancer Genome Atlas 
(TCGA) Research Network [2]. In this comprehensive study, ge-
nomic and epigenomic abnormalities were measured on clini-
cally annotated high-grade serous ovarian cancer (HGS-OvCa) 
to identify the molecular mechanism of the pathophysiology 
that constitutes effective therapeutic targets. TCGA project has 
analyzed messenger RNA expression, microRNA expression, 
promoter methylation, and DNA copy number in 489 HGS-
OvCa in addition to the DNA sequences of exons from coding 
genes in 316 of these tumors. The project reported 96% of a 
TP53 mutation rate. BRCA1 and BRCA2 were mutated in 22% 
of tumors owing to a combination of germline and somatic 
mutations. Six other statistically recurrently mutated genes 
were also identified, but only in 2-6% of HGS-OvCa: RB1, NF1, 
FAT3, CSMD3, GABRA6, and CDK12. They also identified, they 
believe, rare but important driver mutations in HGS-OvCa be-
cause of transforming activity: BRAF, PIK3CA, KRAS, and NRAS. 
The study found 113 significant focal somatic copy number 
alterations (SCNAs), the most common focal amplifications of 
which encoded CCNE1, MYC, and MECOM as well as promoter 
methylation events involving 168 genes. A high prevalence of 
mutations and promoter methylation in putative DNA repair 
genes, including a homologous recombination component, 
might explain the high prevalence of SCNAs. Homologous 
recombination defects might be present in approximately half 
of all HGS-OvCa cases, providing a rationale for clinical trials of 
poly (ADP-ribose) polymerase (PARP) inhibitors. Finally, differ-
ent mutation spectrums between ovarian cancer histological 
subtypes were suggested as a rationale of subtype-specific 
care. Examples are few TP53 mutations but recurrent ARID1A 
and PIK3CA mutations in clear-cell ovarian cancer; frequent 
CTNNB1, ARID1A, and PIK3CA mutations in endometrioid 
ovarian cancer; and KRAS mutations in mucinous ovarian can-
cer.
The second major study was by van Dam et al. [3] and con-
cerned a new intraoperative imaging technique using a folate 
receptor-α (FR-α) targeted fluorescent agent. The research-
ers tried to develop a real-time tumor-specific surgical visual-
ization system with a detection power up to the submillimeter 
level because the degree of cytoreduction is one of the most 
important prognostic factors in ovarian cancer. This study 
used 10 subjects that comprised four ovarian cancers (two 
serous carcinomas, one undifferentiated and one mucinous 
carcinoma), one serous borderline tumor, and five benign 
ovarian tumors (two fibrothecomas, one cellular fibroma, one 
cystic teratoma, and one benign multicystic ischemic ovary). 
Using flourescein isothiocyanate conjugated folate (folate-
FITC) for targeting FR-α, which was overexpressed in 90-95% 
of malignant tumors, fluorescence was detectable intraopera-
tively in all patients with a malignant tumor and FR-α expres-
sion, but not in those with benign tumors. Thus, the real-time 
image-guided excision of fluorescent tumor deposits of size 
<1 mm was feasible. Tumor-specific fluorescent signals could 
be detected from two to eight hours after injection of folate-
FITC intravenously. Van Dam et al. [3] suggested several ad-
vantages of the intraoperative fluorescence imaging system: 
avoiding needless extensive surgical procedures and associ-
ated morbidity thanks to a large field of view for inspection 
and staging; contributing to more efficient cytoreduction and 
ultimately improving the effect of adjuvant chemotherapy in 
patients with reduced tumor burden. It was true particularly 
when combined with hyperthermic intraperitoneal chemo-
therapy (HIPEC) [4]. The promising value of an intraoperative 
imaging system appeared valid even in a laparoscopic setting 
and interval debulking surgery after chemotherapy because 
FR-α expression in the remaining vital tumor tissue was not 
significantly altered after chemotherapy. 
The diagnostic and therapeutic values of integrated genom-
ic approaches and intraoperative tumor-specific fluorescence 
imaging in staging and debulking surgery for ovarian cancer 
need confirmation by further studies. 
UPDATES OF BEVACIZUMAB IN OVARIAN CANCER
Unfortunately, no final report on international, multicenter, 
randomized controlled trials for antiangiogenic agents in 
ova  rian cancer was published in full this year. However, three 
important updates of previously reported phase III studies 
were presented at the American Society of Clinical Oncology 
(ASCO) Annual Meeting in 2011. First, updates of two front-
line bevacizumab studies were presented. The independent 
radiologic review of GOG 218 confirmed a preliminary result 
of a study published last year. In other words, the addition of 
15 mg/m
2 of bevacizumab every 3 weeks during both 6 cycles 
of paclitaxel (175 mg/m
2)/carboplatin (AUC 6) and 16 cycles 
of maintenance drug alone (16 months of total duration) (arm 
III) prolonged progression-free survival (PFS) of paclitaxel/car-
boplatin alone (arm I) by 6 months (hazard ratio [HR], 0.63; p< 
0.0001) [5]. The second updated study was a subgroup analy-
sis of poor prognosis patients by International Collaborative 
Ovarian Neoplasm (ICON) 7 [6]. Based on the mature results of 
PFS benefit (p=0.0041, a 15% improvement at 12 months and 
1.5 months overall) and preliminary overall survival (OS) data 
(HR, 0.81; 95% confidence interval [CI], 0.63 to 1.04; p=0.098) 
of last year, the overall trend for improvement in OS due to 
the administration of bevacizumab continued in the highest 
risk group of patients, which had large volumes of residual Major clinical research advances in gynecologic cancer in 2011
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disease and stage IV (HR, 0.64; 95% CI, 0.48 0.85; p=0.002). Ac-
cording to Gaitskell et al.’s meta-analysis of two trials [7], GOG 
218 and ICON 7, of women who received both concurrent and 
maintenance bevacizumab in addition to chemotherapy had 
significantly lower risk of disease progression compared with 
women who received concurrent and maintenance placebo 
or no further treatment in addition to their chemotherapy (HR, 
0.75; 95% CI, 0.68 to 0.83). However, meta-analysis found no 
statistically significant difference in OS between women who 
received concurrent and maintenance bevacizumab in addi-
tion to chemotherapy, and women who received concurrent 
and maintenance placebo or no further treatment in addition 
to chemotherapy (HR, 0.87; 95% CI, 0.73 to 1.03). 
Lastly, Aghajanian et al. [8] reported the preliminary results 
of the OCEANS trial, which was the first phase III trial of an 
antiangiogenic agent to demonstrate a clinical benefit to 
platinum-sensitive recurrent epithelial ovarian cancer (EOC), 
primary peritoneal (PPC), and fallopian tube cancer (FTC). A 
total of 484 patients were evenly randomized to arm A (control 
group), who received 6 cycles of gemcitabine (1,000 mg/m
2, 
day 1 and 8), carboplatin (AUC 4, day 1), and placebo (day 1) 
every three weeks, which was followed by tri-weekly mainte-
nance placebo until disease progression, and arm B (experi-
mental group), who received 6 cycles of gemcitabine/carbo-
platin with bevacizumab (15 mg/kg, day 1) every three weeks, 
which was followed by tri-weekly maintenance bevacizumab 
until disease progression. During the median follow-up of 24 
months, arm B significantly increased PFS compared to arm A 
(12.4 vs. 8.4 months; HR, 0.484; p<0.0001). Despite the imma-
ture OS data, the bevacizumab group showed a comparably 
higher overall response rate (78.5% vs. 57.4%; p<0.0001) and 
longer duration of response (10.4 vs. 7.4 months; p<0.0001) 
without any new safety concerns. 
In contrast to the OCEANS trial in platinum-sensitive cancers 
is the ongoing phase III trial of bevacizumab in platinum-re-
sistant settings, namely AURELIA, which is a multicenter, open 
label, randomized, two-arm phase III trial of bevacizumab plus 
chemotherapy versus chemotherapy alone in patients with 
platinum-resistant EOC, FTC, or PPC. All patients enrolled in 
the AURELIA trial receive chemotherapy with either paclitaxel 
or topotecan or liposomal doxorubicin. Of those, bevacizum-
ab (10 mg/kg bi-weekly or 15 mg/kg tri-weekly) is injected 
concomitantly only in the patients randomized to arm 2. The 
primary endpoint is PFS. The release of preliminary data is ex-
pected soon. At present, no sufficient evidence has confirmed 
whether there is a survival benefit from the use of bevacizum-
ab in the treatment of ovarian cancer.
NEW HOPE FOR TREATMENT OF OVARIAN CANCER
Despite the somewhat disappointing results of phase III trials 
of molecular targeted agents in ovarian cancer, some promis-
ing reports of phase I-II studies keep alive the hope for treat-
ment of ovarian cancer.
PARP facilitates DNA repair by binding to DNA breaks and 
attracting DNA repair proteins to the site of damage. Two piv-
otal experimental studies in 2005 showed preclinical efficacy 
of PARP inhibitors in tumors with homologous DNA repair 
defects, such as those arising in BRCA1 or BRCA2 mutation 
carriers with ovarian cancer [9,10]. Subsequent phase I and II 
studies of BRCA1 or BRCA2 mutations carriers have confirmed 
the activity of the PARP inhibitor, olaparib, with an objective 
response rate of 33% in patients with ovarian cancer [11,12]. 
However, the efficacy of PARP inhibitors was established only 
in a population with germline mutations in the BRCA1 and 
BRCA2 genes, which accounted for only about 10% of epithe-
lial ovarian cancer [13]. In 2011, two phase II studies showed 
the activity of olaparib in women with high-grade serous 
ovarian cancer who did not have germline BRCA1 or BRCA2 
mutations. The first study was a phase II, multicenter, open-
label, non-randomized study with 91 patients (65 ovarian and 
26 breast cancer) [14]. Objective response rates by the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) were 41% 
(7/17) and 24% (11/46) in patients with and without BRCA1 
or BRCA2 mutations, respectively. No serious adverse events 
were observed. The second study was presented by Leder-
mann [15] at the ASCO Annual Meeting in 2011. A total of 265 
patients with platinum-sensitive relapsed serous ovarian can-
cer were randomized regardless of BRCA1 or BRCA2 mutations 
status (136 to oral olaparib 400 mg bid and 129 to placebo). 
PFS by RECIST was significantly longer in the olaparib than 
the placebo group (HR, 0.35; 95% CI, 0.25 to 0.49; p<0.00001; 
median 8.4 versus 4.8 months). The majority of adverse events 
were CTCAE grade 1 or 2, nausea, fatigue, vomiting, and ane-
mia. Additional phase II trials of the PARP inhibitor, iniparib, in 
combination with gemcitabine/carboplatin in patients with 
platinum-sensitive and platinum-resistant recurrent ovarian 
cancer were also presented at the ASCO Annual Meeting in 
2011 [16,17]. Compared with data from previous studies, the 
preliminary analyses of 17 patients with platinum-sensitive 
recurrent ovarian cancer and 19 patients with platinum-resis-
tant recurrent ovarian cancer demonstrated increased overall 
response rates (70.6% vs. 47.2% and 31.6% vs. 11.7%, respec-
tively) without unexpected toxicities. These findings confirm 
the hypothesis that patients with common sporadic tumors 
can be targeted effectively with PARP inhibitor therapy [13]; 
thus, further assessment of the drug in clinical trials is needed. Dong Hoon Suh, et al.
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Finally, a phase I trial of another molecular targeted option, 
the AKT inhibitor (GSK2141795) was presented at the Euro-
pean Multidisciplinary Cancer Congress, 2011, in Stockholm, 
Sweden [18]. This small study showed 3 responses, one of 
which was a patient with clear cell carcinoma who had muta-
tions of the PI3/AKT pathway. Considering that clear cell car-
cinoma is one of the most difficult subtypes to treat, the AKT 
inhibitor needs to be studied in further clinical trials because 
clear cell carcinoma has a high frequency of the mutation. 
QUALITY OF LIFE OF POST-RISK-REDUCING SALPINGO-
OOPHORECTOMY SURVIVORS
Risk-reducing salpingo-oophorectomy (RRSO) is currently 
recommended for BRCA 1/2 mutation carriers at the comple-
tion of the childbearing years between the ages of 35 and 40 
or younger in carriers with a familial cancer history of early 
onset [19-21]. According to the report from a research group 
at the MD Anderson Cancer Center, the majority of women 
who were at high risk for breast and ovarian cancer were sat-
isfied with their choice of a risk-reduction strategy [22], the 
standard practice of RRSO according to the recommendation 
has increased the number of post-RRSO survivors who are at 
risk of primary peritoneal cancer, bone loss, and menopausal 
symptoms [23]. However, there is a lack of post-RRSO health 
care guidelines for this cohort of patients. 
In 2011, several studies focused on post-RRSO care. An ab-
stract regarding the impact of hormone replacement therapy 
(HRT) on the risk of breast cancer in post-RRSO survivors was 
presented at the ASCO Annual Meeting in 2011 [24]. In 1229 
BRCA1 (n=795) and BRCA2 (n=504) mutation carriers, HRT 
following RRSO was not associated with an increased risk of 
breast cancer compared with those with no RRSO (HR, 0.46, 
95% CI, 0.28 to 0.76 vs. HR, 0.51, 95% CI, 0.32 to 0.80). In BRCA1 
mutation carriers, HRT used both with (HR, 0.52) and without 
(HR, 0.29) RRSO was associated with a decreased risk of breast 
cancer. Another study, conducted by Challberg et al. [25], 
used a questionnaire. They evaluated menopausal symptoms 
and bone health in 212 questionnaire respondents (response 
rate 73%) who underwent RRSO before the age of 48. The 
percentage of patients currently on HRT who experienced 
“very much” or “quite a bit” appeared to be less for hot flushes, 
night sweats and vaginal dryness than those who had never 
used HRT or previous HRT users. Bone loss with a T score of 
less than -1.0 was present in 5 out of 31 (16%) women with no 
period of estrogen deprivation before 50 years compared with 
37 out of 78 (47%) of those with more than 24 months of es-
trogen deprivation (p=0.03). They recommended that women 
undergoing RRSO before 50 years should be counseled con-
cerning the risk and benefits of HRT because the risks of breast 
cancer from estrogen-only HRT appeared to be relatively 
small. Cohen et al. [26] also reported high rates of osteopenia 
and osteoporosis in a cohort of BRCA1/2 mutation carriers 
with breast cancer undergoing RRSO prior to 50. However, six 
of 10 (60%) patients who reported no history of dual-energy 
X-ray absorptiometry (DXA) bone scan said that their non-use 
was because the “MD did not recommend screening,” and 
two out of six (33%) patients with menopausal symptoms not 
receiving HRT and with no known contraindication to its use 
were advised against HRT by their physicians [23]. Based on 
this study’s result, therefore, Chapman et al. [23] concluded 
that the inconsistent post-RRSO care was attributed to the 
lack of post-RRSO health care guidelines and proposed guide-
lines. Further work on the development of standardized post-
RRSO health care guidelines is therefore necessary.
THE RISK OF OVARIAN MALIGNANCY ALGORITHM (ROMA): 
HE4 AND CA-125
According to the final report in 2011 of the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening Trial, simul-
taneous screening with CA-125 and transvaginal ultrasound 
compared with usual care did not reduce ovarian cancer 
mortality [27]. However, we are currently expecting the final 
results of the United Kingdom Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS), which is based on the promis-
ing preliminary findings of 2009 regarding the prevalence 
screening of ovarian cancer [28]. 
Apart from effective screening of the general population, risk 
evaluation for epithelial ovarian cancer in women with pelvic 
mass was another important issue to be established. Since the 
first report of the good performance of the dual marker com-
bination of human epididymis protein 4 (HE4) and CA-125 for 
risk prediction of ovarian malignancies by Moore et al. [29] in 
2009, the performance of the combination of HE4 and CA-125 
values has been investigated for effective triage of women 
with a pelvic mass: risk of ovarian malignancy algorithm 
(ROMA). 
A prospective validation study of ROMA analyzed the per-
formance of HE4, CA-125, and ROMA of 389 patients with 
a pelvic mass [30]. The study failed to demonstrate better 
performance of ROMA than CA-125 alone (receiver operator 
characteristic-area under curve [ROC-AUC], 0.898 vs. 0.877). 
Despite the excellent ability of HE4 to discriminate between 
endometriosis and ovarian cancer, ovarian cancer will cause a 
raised CA-125 and HE4, whereas endometriosis will only cause Major clinical research advances in gynecologic cancer in 2011
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a raised CA-125. Even for pre-menopausal patients, HE4 and 
ROMA did not perform better than CA-125. This is in contrast 
to the previous results of Moore et al. [29], who found that a 
combination of CA-125 and HE4 performed better than CA-
125 alone. Furthermore, they suggested the chances of HE4 
or ROMA as a successful screening marker were low because 
very high specificities were required in screening for low prev-
alent disease. 
Another large study on ROMA was conducted by Bandiera et 
al. [31], who analyzed the performance of HE4 and ROMA with 
preoperative serum samples from 419 women, of which 140 
were healthy controls, 131 were ovarian benign cysts, 34 were 
endometriosis, and 114 were epithelial ovarian cancers. For 
the discrimination of benign masses from epithelial ovarian 
cancers in premenopausal women, the sensitivity and specific-
ity were 92.3% and 59.4% for CA-125, 84.6% an 94.2% for HE4, 
and 84.6% and 81.2% for ROMA, whereas in postmenopausal 
women, the sensitivity and specificity were 94.3% and 82.3% 
for CA-125, 78.2% and 99.0% for HE4, and 93.1% and 84.4% for 
ROMA. Multivariate analysis revealed that elevated HE4 and 
ROMA were independent prognostic factors for shorter OS 
and PFS. The inconsistency of these results provides a ratio-
nale for researchers to perform multicenter studies in order to 
draw firm conclusions.
RATIONALES OF PROMOTION OF HPV VACCINE COVERAGE 
IN LOW-RESOURCE REGIONS
In 2011, three influential study results gave an additional 
explanation for the reason that we should focus human papil-
lomavirus (HPV) vaccination efforts in low-resource regions to 
reduce cervical cancers efficiently: cross-protective efficacy; 
the efficacy of fewer than three doses of a bivalent HPV 16/18 
vaccine; and early effect of the HPV vaccination program. A 
pair of four-year end-of-study analyses of the randomized, 
double-blind Papilloma Trial against Cancer in Young Adults 
(PATRICIA) trial reported strong evidence for near 100% pro-
phylactic vaccine efficacy in HPV-naive women at any age and 
cross-protective efficacy of the HPV 16/18 vaccine [32,33]. A 
total of 46,402 healthy women aged 15-25 years with no more 
than six lifetime sexual partners were randomized to HPV 
16/18 vaccine or a control hepatitis A vaccine and analyzed 
to estimate the extent of cross-protection. Vaccine efficacy 
was evaluated against six-month persistent infection, cervical 
intraepithelial neoplasia 2 or greater (CIN II+) associated with 
12 non-vaccine HPV types, and CIN III+ associated with the 
composite of 12 non-vaccine HPV types. Consistent vaccine 
efficacy of the HPV 16/18 vaccine against persistent infection 
and CIN II+ was seen for HPV-33, 31, 45, and 51, which showed 
cross-protective efficacy of the HPV 16/18 vaccine against four 
oncogenic non-vaccine HPV types. 
Kreimer et al. [34] evaluated the vaccine efficacy of fewer 
than three doses of the HPV 16/18 vaccine in the Costa Rica 
vaccine trial. Because many of the 7,153 women missed one 
or more of three doses of a randomly assigned HPV16/18 
vaccine or control (hepatitis A) vaccine, vaccine efficacy was 
evaluated in each dosage group by determination of the 
number of newly detected HPV 16 or HPV 18 infections that 
persisted at least one year. They found that incident HPV 16 
or HPV 18 infections that persisted for 1 year were not related 
to dosage of the control vaccine. Specifically, vaccine efficacy 
was 80.9%, 84.1%, and 100% for three, two, and one dose(s) of 
the HPV vaccine, respectively. They concluded that two doses 
of the HPV 16/18 vaccine, and maybe even one dose, were as 
protective as three doses in protecting against persistent HPV 
16/18 infections. 
Lastly, an Australian ecological study reported the early ef-
fect of the HPV vaccination program on cervical abnormali-
ties [35]. They compared the incidence of high-grade cervical 
abnormalities (HGAs) and low-grade cytological abnormalities 
(LGAs) before and after the vaccination program began. A de-
crease in the incidence of HGAs by 0.38% (95% CI, 0.61 to 0.16) 
in girls younger than 18 years was observed after the intro-
duction of the vaccination program. However, no similar tem-
poral decline was recorded for LGAs or in older age groups. 
This study was the first to report the effect of a national HPV 
vaccination program on cervical abnormalities at a popula-
tion level. The fact that the decrease in the incidence of HGA 
in young women soon after the implementation of the vac-
cination program suggested that we should begin screening 
women at a young age because of the high cost-effectiveness 
of this young age group. From a public health perspective, the 
cost-effectiveness of increasing HPV vaccine coverage seems 
very important in preventing cervical cancer in low-resource 
settings. These three findings in 2011 support the evidence 
for improving cost-effectiveness. 
Of note were efficacy and safety reports of quadrivalent 
HPV vaccine against anal HPV infection and anal intraepi-
thelial neoplasia [36]. Of 602 men who have sex with men, 
432 (71.8%) had completed the protocol. Each 299 were vac-
cinated with quadrivalent HPV vaccine and with placebo, 
respectively. Efficacy of the quadrivalent HPV vaccine against 
anal intraepithelial neoplasia associated with HPV 6, 11, 16, or 
18 was 50.3% in the intention-to-treat population and 77.5% 
in the per-protocol efficacy population. No vaccine-related 
serious adverse events were observed. Dong Hoon Suh, et al.
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EVIDENCE OF SAFETY AND FEASIBILITY IN HPV-BASED 
CERVICAL CANCER SCREENING 
Based on the better sensitivity of the HPV test than cervi-
cal cytology for the detection of CIN II, CIN III and cancer, co-
screening with HPV and a papanicolau (Pap) test every three 
years for women with normal cytology and negative HPV test 
results is currently recommended by the American Cancer 
Society and American College of Obstetricians and Gynecolo-
gists guidelines [37]. However, only 19% of US clinicians would 
recommend the three-year follow-up with co-screening for 
these women because of the concern about the cancer risk 
accrued over three years [38]. 
Several studies in 2011 yielded safety and feasibility evidence 
for HPV-based cervical cancer screening. The most influential 
was a population-based study in routine clinical practice by 
Katki et al. [39], who showed safety in routine clinical practice 
of three-year screening with HPV test and Pap test for women 
testing negative for HPV with normal cytology (HPV-negative/
Pap-negative) with 331,818 eligible women aged 30 years and 
older. The five-year cervical cancer risk in HPV-negative/Pap-
negative women was 0.016% (3.2/100,000/year), only slightly 
smaller than 0.019% (3.8/100,000/year) risk in HPV-negative 
women (p=0.800). In comparison, the five-year cervical cancer 
risk in Pap-negative women was 0.037% (7.5/100,000/year; 
p=0.300). The results indeed provided support for three-year 
HPV alone-based screening of HPV-negative women because 
they had an extremely low risk of developing cervical cancer 
over five years. On the other hand, abnormal Pap test greatly 
increased the five-year cancer risk for the 16,757 HPV-positive 
women (12.1% vs. 5.9%, p<0.0001). In the HPV-positive wom-
en, Pap test had a significant role in further triage. Interest-
ingly, a higher percentage of disease outcomes was shown 
in HPV-positive/Pap-negative women than in HPV-negative/
Pap-positive women for CIN III or adenocarcinoma in situ 
(35% vs. 4%, p<0.0001), adenocarcinoma in situ (44% vs. 4%, 
p<0.0001), total cancers (29% vs. 10%, p=0.004), and especial-
ly adenocarcinoma (63% vs. 0%, p<0.0001). It suggested that 
incorporating HPV testing with cytology could earlier detect 
women at high risk of cervical cancer, especially adenocarci-
noma, which was poorly identified by Pap tests. 
Evidence for the feasibility of HPV-based cervical cancer 
screening was provided by studies for HPV self-sampling, 
which was counted as alternative strategy of non-attendees 
for cervical cancer screening. According to a recent survey, 
reasons for non-attendance of cervical screening included 
the unpleasant/embarrassing nature of examination, practical 
issues such as lack of time, problems with transport, making 
appointments, and perceptions of being at low risk for disease 
[40]. A recent randomized controlled trial showed a low atten-
dance rate (4.5%) for cytology screening in the control group 
versus a higher total response rate (10.2%) in the self-sampling 
group, which suggested that self-sampled HPV tests could 
be an option for increasing participation in cervical cancer 
screening [40]. In addition, many community-based random-
ized controlled trials showed the higher sensitivity of the self-
sampled HPV test than clinic-based cervical cytology to detect 
invasive cervical cancer (odds ratio [OR], 4.2 [41], 5.4 [42], and 
2.8 [43]). Therefore, we can overcome some of the practical 
and emotional barriers to screening attendance by means of 
a self-sampled HPV test in both developed countries and low 
resource regions with a lack of infrastructure to maintain high 
quality laboratory results. 
TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER
Since the paradigm change in 1999 for the treatment of lo-
cally advanced cervical cancer from radiation therapy alone to 
cisplatin-based chemoradiation [44], no study has suggested 
an adjuvant therapeutic regimen that showed additional sur-
vival benefits in patients with locally advanced cervical cancer 
until a recent phase III randomized trial by Duenas-Gonzalez 
et al. [45]. They demonstrated that gemcitabine-cisplatin 
chemoradiation followed by brachytherapy and adjuvant 
gemcitabine-cisplatin chemotherapy (arm A) improved both 
PFS (HR, 0.68; 95% CI, 0.49 to 0.95; p=0.022) and OS (HR, 0.54; 
95% CI, 0.37 to 0.79; p=0.001) compared with cisplatin-based 
chemoradiation followed by brachytherapy alone (arm B). 
Grade 3 and 4 toxicities, most commonly hematologic toxici-
ties, neutropenia, were more frequent in arm A than arm B 
(86.5% vs. 46.3%, respectively; p<0.001). Of the three deaths 
that occurred in arm A during or within 30 days of the study 
treatment, two were possibly related to study treatment toxic-
ity. Therefore, concerns about treatment-related deaths make 
this regimen difficult to accept as a standard-of-care without a 
more careful study regarding late toxicity [46].
We expect positive results from three Gynecologic Cancer 
Intergroup (GCIG) clinical trials for locally advanced cervical 
cancer, which have just begun or are just going to begin: 
OUTBACK, INTERLACE (Induction Chemotherapy in Locally 
Advanced Cervical Cancer), and TACO (Tri-weekly Administra-
tion of Cisplatin in Locally Advanced Cervical Cancer) trials. 
First, the OUTBACK trial is a phase III trial of adjuvant chemo-
therapy following chemoradiation as the primary treatment 
for patients with stage IB1 and positive LNs, IB2, II, IIIB or IVA 
cervical cancer compared with chemoradiation alone. Led by 
the Australia & New Zealand Gynecological Oncology Group Major clinical research advances in gynecologic cancer in 2011
J Gynecol Oncol Vol. 23, No. 1:53-64 www.ejgo.org 59
(ANZGOG), the OUTBACK trial opened to recruitment in March 
2011 with OS as the primary endpoint. The recruitment target 
is 780 participants. Second, the INTERLACE trial, which is led 
by the Medical Research Council/National Cancer Research 
Institute (NCRI), is a phase III multicenter trial of weekly induc-
tion chemotherapy (paclitaxel 80 mg/m
2 plus carboplatin 
AUC2) followed by standard chemoradiation versus standard 
chemoradiation alone in patients with locally advanced cervi-
cal cancer. INTERLACE opened to recruitment July 2011. Lastly, 
the TACO trial was proposed by both by Dr. Ryu of the Korean 
Gynecologic Oncology Group (KGOG) and by Dr. Wilailak of 
the Thai Gynecologic Cancer Society (TGCS) (KGOG 1027/THAI 
2012). It is based on the positive results of five-year survival of 
a pilot randomized trial of weekly versus tri-weekly cisplatin-
based chemoradiation in locally advanced cervical cancer 
(88.7% vs. 66.5%, respectively; HR, 0.375; 95% CI, 0.154 to 0.914; 
p=0.03) [47]. The principal investigators are now preparing 
to launch the TACO trial as an international, multicenter, ran-
domized phase III trial comparing six cycles of weekly cisplatin 
40 mg/m
2 with three cycles of tri-weekly cisplatin 75 mg/m
2 
for chemoradiation in locally advanced cervical cancer. We 
expect new treatment regimens to bring significant improve-
ment in the near future to the survival rates of patients with 
locally advanced cervical cancer. 
SENTINEL-NODE BIOPSY IN EARLY STAGE ENDOMETRIAL 
CANCER
For early endometrial cancer, the prognostic relevance of asse-
ssing lymph node status by lymphadenectomy is still controver-
sial although randomized controlled trials and a meta-analysis 
have shown that pelvic lymph node dissection (PLND) has no 
effect on patient survival and leads to a high incidence of re-
lated complications [48-50]. Therefore, tremendous effort has 
been concentrated on preoperative or intraoperative predic-
tion of LN metastasis to identify the indication of systematic 
lymphadenectomy, but without success. A meta-analysis by 
Selman et al., suggested that sentinel node biopsy is more 
accurate than MRI and CT scan in assessing LN status in en-
dometrial cancer [51]. The main interest in the sentinel-node 
concept for patients with early stage endometrial cancer is 
the reduction of the morbidity of extensive surgical staging by 
lymphadenectomy while accurately identifying patients who 
will benefit from adjuvant therapy. 
A prospective multicenter study published in 2011 showed 
the detection rate and diagnostic accuracy of sentinel LN 
biopsy in early stage endometrial cancer (SENTI-ENDO) [52]. 
A total of 133 patients with stage I-II endometrial cancer 
had pelvic sentinel LN assessment via cervical dual injection 
with technetium and patent blue. In accordance with French 
guidelines, the extent of lymphadenectomy was determined 
according to preoperative pathological results [53]. All pa-
tients with type 1 endometrial cancer (endometrioid) had pel-
vic lymphadenectomy after removal of the sentinel LNs. A pa-
ra-aortic lymphadenectomy was recommended if metastases 
were detected on intraoperative histology or after definitive 
histology; 15 (12%) patients underwent para-aortic lymphad-
nectomy. All patients belonged to one of the three risk groups 
defined by FIGO classification in 2009: 57 low risk-type 1 en-
dometrial cancer, stage IA grade 1 or 2; 33 intermediate risk 
type 1 endometrial cancer, stage 1A grade 3, or stage IB grade 
1 or 2; and 16 high risk type 1 endometrial cancer, sage IB 
grade 3, or type 2 endometrial cancer; or any stage and grade 
[54]. At least one sentinel LN was detected in 89% of eligible 
patients (111 of 125). The clinical value of sentinel LN biopsy is 
based on its reliable negative predictive value (NPV) and high 
sensitivity to detect metastatic disease [55]. In this study, NPV 
and sensitivity showed 100% for each hemipelvis as a unit. 
However, NPV dropped to 97%, but was still high when the 
patient was considered as the unit of analysis because senti-
nel LN was not involved in three of the 19 patients who had 
pelvic LN metastases (two in contralateral pelvic area and one 
in the para-aortic area). Of the 16 patients with positive sen-
tinel LNs, 6, 5, and 5 occurred in patients with low, intermedi-
ate, and high risk endometrial cancer, respectively. Notably, 
no LN metastasis other than positive sentinel LN occurred in 
patients with low or intermediate risk endometrial cancer. The 
study suggested that sentinel LN biopsy alone was enough to 
justify adjuvant therapy without the need for complete pelvic 
lymphadenectomy in these patients. However, the high inci-
dence of metastases in both sentinel and non-sentinel LNs in 
patients with high-risk endometrial cancer led to the perfor-
mance of pelvic lymphadenectomy in high risk patients. This 
study seems quite meaningful in that it might suggest the im-
portant role of a sentinel LN biopsy in the triage for the extent 
of lymphadenectomy in early endometrial cancer. 
EFFECTIVE STRATEGIES FOR PREVENTION AND TREATMENT 
OF BREAST CANCER
In 2011, two notable achievements in the field of breast 
cancer research were for the prevention and the treatment of 
metastatic disease, respectively. 
The first study was a randomized, placebo-controlled, dou-
ble-blind trial for the efficacy of exemestane, an aromatase 
inhibitor, in the prevention of breast cancer in postmeno-Dong Hoon Suh, et al.
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pausal women [56]. This study was initiated to overcome the 
low acceptance of tamoxifene or raloxifene for reducing the 
risk of breast cancer, partly because of rare but serious toxic 
effects [57-61]. The eligibility criteria included postmeno-
pausal women 35 years of age or older with at least one of the 
following risk factors: 60 years or older; Gail 5-year risk score 
greater than 1.66% (chances in 100 of invasive breast cancer 
developing within 5 years); prior atypical ductal or lobular hy-
perplasia or lobular carcinoma in situ; ductal carcinoma in situ 
with mastectomy. A total of 4560 women were randomized to 
exemestane (2,285 patients) or placebo (2,275 patients). The 
primary outcome was the incidence of invasive breast can-
cer. At a median follow-up of 35 months, 11 and 32 invasive 
breast cancers were diagnosed in the exemestane group and 
the placebo group, respectively (annual incidence, 0.19% vs. 
0.55%; HR, 0.35; 95% CI, 0.18 to 0.70; p=0.002). Adverse events 
occurred in 5% or more of subjects, 88% in the exemestane 
group versus 85% in the placebo group (p=0.003). Arthritis 
(p=0.01) and hot flushes (p<0.001) were more common in the 
exemestane group. The major reason for early discontinuation 
of the protocol treatments were toxic effects (15.4% vs. 10.8%, 
p<0.001). However, the researchers concluded that, with its 
excellent safety profile, exemestane significantly reduced in-
vasive breast cancers in postmenopausal women who were at 
moderately increased risk for breast cancer, based on the simi-
larity between the two groups in terms of skeletal fractures, 
car  diovascular events, other cancers, or treatment related deaths.
Second was the phase III open-label randomized study, which 
focused on eribulin monotherapy versus treatment of physician’s 
choice (TPC) in patients with metastatic breast cancer (EMBRACE) 
[62]. It was not until EMBRACE that a biological agent showed 
significant improvement of OS in patients with heavily pre-
treated metastatic breast cancer. Eribulin mesilate is a non-
taxane inhibitor of microtubule dynamics in the hali  chondrin 
class of antineoplastic drugs. Based on the promising results 
of phase II eribulin studies, EMBRACE enrolled a total of 762 
women who were randomly allocated to either the eribulin 
group (508 patients) or the TPC group (254 patients). In parti-
cular, EMBRACE used the TPC group as a control group in or-
der to mirror clinical practice at the time in this setting. OS for 
eribulin was significantly increased compared with TPC group 
(HR, 0.81; 95% CI, 0.66 to 0.99; p=0.041), with median OS 13.1 
and 10.6 months in patients receiving eribulin and those assi-
g  ned TPC, respectively. While asthenia and fatigue were the 
most common adverse events in both groups, peripheral neu-
ropathy was the most common adverse event leading to the 
discontinuation of eribulin (5%). Considering its manageable 
toxi  city profile, relative ease of administration, short infusion 
time, and no requirement for premedication to prevent hy-
per  sensitivity, eribulin was suggested by this study as a new 
po  tential standard drug for women with heavily pretreated 
metastatic breast cancer. 
PREVENTION OF CHEMOTHERAPY-INDUCED EARLY 
MENOPAUSE IN BREAST CANCER
Approximately 6% of women with breast cancer are diag-
nosed before age of 40 years [63]. Premenopausal women 
with breast cancer are at high risk of early menopause be-
cause most of young patients with breast cancer receive a 
certain combination of systemic chemotherapy and hormonal 
therapy considering the adverse outcome of young patients 
[64]. Gerber et al. [65] made a rough estimate that each month 
of chemotherapy translated into 1.5 years of lost reproduc-
tive life. Based on the promising results of preclinical and early 
clinical data of ovarian protective effect of a gonadotropin-
releasing hormone (GnRH) analogue during chemotherapy 
[66,67], a randomized, phase 3 superiority trial was conducted: 
Prevention of Menopause Induced by Chemotherapy: A Study 
in Early Breast Cancer Patients-Gruppo Italiano Mammella 6 
(PROMISE-GIM6) [63]. Of 281 premenopausal women with 
stage I-III breast cancer, 133 and 148 were allocated to receive 
chemotherapy alone and chemotherapy plus GnRH analogue, 
triptorelin, respectively. Triptorelin was administered intramus-
culary at a dose of 3.75 mg at least 1 week before chemother-
apy and then every 4 weeks for the duration of chemotherapy. 
Primary endpoint was early menopause which was defined 
as no resumption of menstrual activity and postmenopausal 
levels of follicle-stimulating hormone and estradiol 1 year after 
the last cycle of chemotherapy. The rate of early menopause 
was 25.9% in the chemotherapy-alone group and 8.9% in the 
chemotherapy plus triptorelin group with OR for treatment-
related early menopause 0.28 (95% CI, 0.14 to 0.59; p<0.001). 
The role of GnRH analogue in preserving ovarian function 
during chemotherapy for breast cancer is still controversial 
[68]. Despite the lack of data concerning the long-term main-
tenance of ovarian function and veiled mechanisms of action 
of GnRH analogues preserving ovarian function, PROMISE-
GIM6 is the largest study that showed temporarily suppress-
ing ovarian function by administering triptorelin reduced the 
incidence of chemotherapy-induced early menopause in pre-
menopausal women with early-stage breast cancer.  
CONCLUSION
Despite enormous efforts in research, the prognosis of ovar-Major clinical research advances in gynecologic cancer in 2011
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ian cancer is still very poor. However, integrated genomic 
analyses of ovarian cancer by TCGA might yield opportunities 
to improve the prognosis of ovarian cancer through subtype-
specific etiological approaches. Moreover, maximal cytore-
duction through a real-time tumor-specific surgical visualiza-
tion system using a FR-α targeted fluorescent agent might 
enhance the therapeutic effect of conventional cytoreductive 
surgery as well as subsequent chemotherapy. For cost-effec-
tiveness in low resource settings, HPV vaccination could be 
recommended more actively in order to reduce the high inci-
dence of cervical cancer. We hope that SENTI-ENDO study will 
be influential in suggesting guidelines for the management of 
PLND in patients with early-stage endometrial cancer. Regard-
ing breast cancer, the agents, exemestane and eribulin, are 
expected to be effective in reducing the incidence of breast 
cancer and improving the poor prognosis of heavily treated 
metastatic breast cancer, respectively. Furthermore, GnRH an-
alogues might be offered with solider evidence to premeno-
pausal patients with breast cancer who wish to decrease the 
risk of premature ovarian failure associated with chemother-
apy. Finally, we expect that more practice-changing studies 
will be performed in the field of gynecologic oncology in the 
coming year.
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